Venlafaxine extended-release in patients older than 80 years with depressive syndrome
Venlafaxine extended-release in patients older than 80 years with depressive syndrome
复制标题
DOI：
10.1002/gps.1468
复制
发表时间：
2006-04-01
影响因子：
4
通讯作者：
Prieto, R
中科院分区：
文献类型：
--
作者：
Baca, E;Roca, M;Prieto, R
目的：本评价的目的是评估文拉法辛缓释（ER）在非常古老的初级保健门诊患者抑郁综合征和相关的焦虑symptoms.Methods的疗效和安全性：这是一个观察性，自然主义，多中心，前瞻性，开放标签研究，在门诊人群中诊断为抑郁综合征与焦虑症状。要求汉密尔顿抑郁量表（HAM-D-17）和焦虑量表（HAM-A）的最低评分分别为17和10。每日剂量为75 mg至225 mg的文拉法辛缓释剂（ER）给药24周。使用HAM-D-17和HAM-A量表评估抑郁-焦虑抑郁症的有效性。患者：本报告中讨论的97例患者是一个亚组，包括所有年龄>= 80岁的老年患者，他们是更大的观察性、自然主义、多中心、前瞻性、开放标签研究的一部分，接受文拉法辛ER治疗的最长持续时间为24周。在终点，缓解率为57.1%（HAM-D-17
Objectives: The aim of this evaluation was to assess the efficacy and safety of venlafaxine extended-release (ER) in very old primary care out-patients with depressive syndrome and associated anxiety symptoms.Methods: This was an observational, naturalistic, multicenter, prospective, open-label study in an outpatient population with a diagnosis of depressive syndrome with anxiety symptoms. Minimum scores of 17 and 10 on the Hamilton Rating Scale for Depression (HAM-D-17) and Anxiety (HAM-A), respectively, were required. Daily doses of 75 mg to 225 mg of venlafaxine extended release (ER) were administered for 24 weeks. Effectiveness for depressive-anxious symptomatology was assessed using the HAM-D-17 and HAM-A scales.Patients: The 97 patients discussed in this report are a subgroup comprising all elderly patients, aged >= 80 years, who were part of the larger observational, naturalistic, multicenter, prospective, open-label study and who had received venlafaxine ER for a maximum duration of 24 weeks.Results: At endpoint, remission rates were 57.1% (HAM-D-17